The development of chimeric antigen receptor (CAR) T-cell therapy for select hematological malignancies represents one of the most remarkable therapeutic advances in the past decade. Currently, CD19-targeted CAR T-cell therapy is approved for relapsed/refractory diffuse large B-cell lymphoma and acute lymphoblastic leukemia. However, there is significant interest in the application of CAR T-cell therapy to other hematological malignancies, including multiple myeloma, where the current focus is on the development of B-cell maturation antigen-directed CAR T-cell therapy. Despite the successes achieved to date, there remain significant challenges associated with CAR T-cell therapy and substantial research efforts are underway to develop new targets and approaches. Here, we provide an overview of the rapidly evolving landscape of CAR T-cell therapy in hematological malignancies and look ahead at the advances that will shape the future of this field.

Original languageEnglish (US)
Pages (from-to)112-122
Number of pages11
JournalClinical Pharmacology and Therapeutics
Issue number1
StatePublished - Jan 1 2020

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress'. Together they form a unique fingerprint.

Cite this